Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience

PURPOSE: There are very little data available comparing outcomes of intensity-modulated proton therapy (IMPT) to intensity-modulated radiation therapy (IMRT) in patients with locally advanced NSCLC (LA-NSCLC). METHODS: Seventy-nine consecutively treated patients with LA-NSCLC underwent definitive IM...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Nathan Y., DeWees, Todd A., Liu, Chenbin, Daniels, Thomas B., Ashman, Jonathan B., Beamer, Staci E., Jaroszewski, Dawn E., Ross, Helen J., Paripati, Harshita R., Rwigema, Jean-Claude M., Ding, Julia X., Shan, Jie, Liu, Wei, Schild, Steven E., Sio, Terence T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276663/
https://www.ncbi.nlm.nih.gov/pubmed/32529140
http://dx.doi.org/10.1016/j.adro.2019.08.001
_version_ 1783542997226356736
author Yu, Nathan Y.
DeWees, Todd A.
Liu, Chenbin
Daniels, Thomas B.
Ashman, Jonathan B.
Beamer, Staci E.
Jaroszewski, Dawn E.
Ross, Helen J.
Paripati, Harshita R.
Rwigema, Jean-Claude M.
Ding, Julia X.
Shan, Jie
Liu, Wei
Schild, Steven E.
Sio, Terence T.
author_facet Yu, Nathan Y.
DeWees, Todd A.
Liu, Chenbin
Daniels, Thomas B.
Ashman, Jonathan B.
Beamer, Staci E.
Jaroszewski, Dawn E.
Ross, Helen J.
Paripati, Harshita R.
Rwigema, Jean-Claude M.
Ding, Julia X.
Shan, Jie
Liu, Wei
Schild, Steven E.
Sio, Terence T.
author_sort Yu, Nathan Y.
collection PubMed
description PURPOSE: There are very little data available comparing outcomes of intensity-modulated proton therapy (IMPT) to intensity-modulated radiation therapy (IMRT) in patients with locally advanced NSCLC (LA-NSCLC). METHODS: Seventy-nine consecutively treated patients with LA-NSCLC underwent definitive IMPT (n = 33 [42%]) or IMRT (n = 46 [58%]) from 2016 to 2018 at our institution. Survival rates were calculated using the Kaplan-Meier method and compared with the log-rank test. Acute and subacute toxicities were graded based on Common Terminology Criteria for Adverse Events, version 4.03. RESULTS: Median follow-up was 10.5 months (range, 1-27) for all surviving patients. Most were stage III (80%), received median radiation therapy (RT) dose of 60 Gy (range, 45-72), and had concurrent chemotherapy (65%). At baseline, the IMPT cohort was older (76 vs 69 years, P < .01), were more likely to be oxygen-dependent (18 vs 2%, P = .02), and more often received reirradiation (27 vs 9%, P = .04) than their IMRT counterparts. At 1 year, the IMPT and IMRT cohorts had similar overall survival (68 vs 65%, P = .87), freedom from distant metastasis (71 vs 68%, P = .58), and freedom from locoregional recurrence (86 vs 69%, P = .11), respectively. On multivariate analyses, poorer pulmonary function and older age were associated with grade +3 toxicities during and 3 months after RT, respectively (both P ≤ .02). Only 5 (15%) IMPT and 4 (9%) IMRT patients experienced grade 3 or 4 toxicities 3 months after RT (P = .47). There was 1 treatment-related death from radiation pneumonitis 6 months after IMRT in a patient with idiopathic pulmonary fibrosis. CONCLUSIONS: Compared with IMRT, our early experience suggests that IMPT resulted in similar outcomes in a frailer population of LA-NSCLC who were more often being reirradiated. The role of IMPT remains to be defined prospectively.
format Online
Article
Text
id pubmed-7276663
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72766632020-06-10 Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience Yu, Nathan Y. DeWees, Todd A. Liu, Chenbin Daniels, Thomas B. Ashman, Jonathan B. Beamer, Staci E. Jaroszewski, Dawn E. Ross, Helen J. Paripati, Harshita R. Rwigema, Jean-Claude M. Ding, Julia X. Shan, Jie Liu, Wei Schild, Steven E. Sio, Terence T. Adv Radiat Oncol Thoracic Cancer PURPOSE: There are very little data available comparing outcomes of intensity-modulated proton therapy (IMPT) to intensity-modulated radiation therapy (IMRT) in patients with locally advanced NSCLC (LA-NSCLC). METHODS: Seventy-nine consecutively treated patients with LA-NSCLC underwent definitive IMPT (n = 33 [42%]) or IMRT (n = 46 [58%]) from 2016 to 2018 at our institution. Survival rates were calculated using the Kaplan-Meier method and compared with the log-rank test. Acute and subacute toxicities were graded based on Common Terminology Criteria for Adverse Events, version 4.03. RESULTS: Median follow-up was 10.5 months (range, 1-27) for all surviving patients. Most were stage III (80%), received median radiation therapy (RT) dose of 60 Gy (range, 45-72), and had concurrent chemotherapy (65%). At baseline, the IMPT cohort was older (76 vs 69 years, P < .01), were more likely to be oxygen-dependent (18 vs 2%, P = .02), and more often received reirradiation (27 vs 9%, P = .04) than their IMRT counterparts. At 1 year, the IMPT and IMRT cohorts had similar overall survival (68 vs 65%, P = .87), freedom from distant metastasis (71 vs 68%, P = .58), and freedom from locoregional recurrence (86 vs 69%, P = .11), respectively. On multivariate analyses, poorer pulmonary function and older age were associated with grade +3 toxicities during and 3 months after RT, respectively (both P ≤ .02). Only 5 (15%) IMPT and 4 (9%) IMRT patients experienced grade 3 or 4 toxicities 3 months after RT (P = .47). There was 1 treatment-related death from radiation pneumonitis 6 months after IMRT in a patient with idiopathic pulmonary fibrosis. CONCLUSIONS: Compared with IMRT, our early experience suggests that IMPT resulted in similar outcomes in a frailer population of LA-NSCLC who were more often being reirradiated. The role of IMPT remains to be defined prospectively. Elsevier 2019-08-21 /pmc/articles/PMC7276663/ /pubmed/32529140 http://dx.doi.org/10.1016/j.adro.2019.08.001 Text en © 2019 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Thoracic Cancer
Yu, Nathan Y.
DeWees, Todd A.
Liu, Chenbin
Daniels, Thomas B.
Ashman, Jonathan B.
Beamer, Staci E.
Jaroszewski, Dawn E.
Ross, Helen J.
Paripati, Harshita R.
Rwigema, Jean-Claude M.
Ding, Julia X.
Shan, Jie
Liu, Wei
Schild, Steven E.
Sio, Terence T.
Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience
title Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience
title_full Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience
title_fullStr Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience
title_full_unstemmed Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience
title_short Early Outcomes of Patients With Locally Advanced Non-small Cell Lung Cancer Treated With Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiation Therapy: The Mayo Clinic Experience
title_sort early outcomes of patients with locally advanced non-small cell lung cancer treated with intensity-modulated proton therapy versus intensity-modulated radiation therapy: the mayo clinic experience
topic Thoracic Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276663/
https://www.ncbi.nlm.nih.gov/pubmed/32529140
http://dx.doi.org/10.1016/j.adro.2019.08.001
work_keys_str_mv AT yunathany earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT deweestodda earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT liuchenbin earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT danielsthomasb earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT ashmanjonathanb earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT beamerstacie earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT jaroszewskidawne earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT rosshelenj earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT paripatiharshitar earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT rwigemajeanclaudem earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT dingjuliax earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT shanjie earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT liuwei earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT schildstevene earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience
AT sioterencet earlyoutcomesofpatientswithlocallyadvancednonsmallcelllungcancertreatedwithintensitymodulatedprotontherapyversusintensitymodulatedradiationtherapythemayoclinicexperience